# The potential health impact of prospective Strep A vaccines: a modeling study

Fiona Giannini,<sup>1</sup> Jeffrey W. Cannon,<sup>1,2</sup> Daniel Cadarette,<sup>2</sup> David E. Bloom,<sup>2</sup> Hannah C Moore,<sup>1,3</sup> Jonathan Carapetis,<sup>1,4</sup> Kaja Abbas<sup>5</sup>

<sup>1</sup>Telethon Kids Institute, University of Western Australia, Perth, Australia

<sup>2</sup> Harvard T.H. Chan School of Public Health, Boston, USA

<sup>3</sup> School of Population Health, Curtin University, Perth, Australia

<sup>4</sup> Perth Children's Hospital, Perth, Australia

<sup>5</sup> London School of Hygiene & Tropical Medicine, London, United Kingdom

Corresponding author: Fiona Giannini (fiona.giannini@telethonkids.org.au)

# Abstract

The World Health Organization published the preferred product characteristics for a Group A *Streptococcus* (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. We used the model to analyse six strategic scenarios. Based on Strep A vaccine introduction between 2022 and 2034 for the primary scenario, we estimated vaccination at birth for 30 vaccinated cohorts could avert 2.5 billion episodes of pharyngitis, 345 million episodes of impetigo, 1.3 million episodes of invasive disease, 24 million episodes of cellulitis, and 6 million cases of rheumatic heart disease globally. Vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for rheumatic heart disease.

**Keywords:** Group A *Streptococcus* (GAS), vaccine impact modeling, pharyngitis, impetigo, Strep A, invasive disease, cellulitis, rheumatic heart disease

# Introduction

Group A *Streptococcus* (Strep A) infection and direct sequelae are a major cause of morbidity and mortality at the global level, with more than half a million deaths annually<sup>1–4</sup> attributable to Strep A. Strep A causes a broad spectrum of diseases, including pharyngitis, impetigo (skin infections), invasive disease, cellulitis, rheumatic heart disease (RHD), acute rheumatic fever (ARF), and acute post-streptococcal glomerulonephritis (APSGN / kidney disease). Children and young adults, particularly those in low- and middle-income countries, are the most affected by ARF and RHD,<sup>5,6</sup> which impose substantial health burden in the form of morbidity and premature mortality due to cardiovascular impairment, as well as a substantial economic burden at the individual, household, and societal levels<sup>7</sup>. While relatively mild compared with RHD, cases and suspected cases of Strep A pharyngitis are major drivers of antibiotic use and misuse<sup>8</sup>, which can contribute to antimicrobial resistance in both Strep A and off-target (bystander) pathogens. While Strep A transmission occurs primarily through infections in the mucosae and skin, the specific dynamics of the transmission pathways are unknown.

The World Health Organization (WHO) published the preferred product characteristics for Strep A vaccines in 2018<sup>9</sup>, which describe the preferred parameters for vaccine indications, target population, data needs for safety and efficacy evaluation, research and development, and vaccination strategies. Strep A infection and disease spectrum is a WHO priority because of the unmet public health need for Strep A vaccines, assessment of technical feasibility, and suitability for use in low- and middle-income countries. While the WHO vision for Strep A vaccines and the near-term strategic goal is to demonstrate good safety and proof of efficacy of a candidate Strep A vaccine against pharyngitis and impetigo in children, the long-term strategic goal is to develop a safe, globally effective, and affordable Strep A vaccine to prevent acute Strep A infections (pharyngitis, impetigo, invasive disease, and cellulitis), avert associated antibiotic use and prevent secondary immune-mediated sequelae (APSGN, ARF, and RHD) and associated mortality.

Based on the WHO's preferred product characteristics, we developed a mathematical model to assess the health impact of vaccination at the global, regional, and national levels and by country-income category. We used this Strep A vaccine impact model to analyse strategic scenarios for varied ages of vaccination (at birth or 5 years of age), vaccine efficacy, dynamics and duration of protection from vaccine-derived immunity, and vaccination coverage.

# Results

We used the vaccine efficacy assumptions (see Table 1) from the WHO preferred product characteristics for a Strep A vaccine and analysed six strategic scenarios (see Table 2) for varied years of vaccine introduction, coverage, and waning dynamics using the Strep A vaccine impact model (see Figure 1). Tables 3 and 4 and Figures 2–4 present the health impact of Strep A vaccination on lifetime disease burden averted among the vaccinated cohorts for the different scenarios.

### Vaccine impact on Strep A cases

Globally, we estimated that vaccination at birth for 30 cohorts assuming country-specific vaccine introduction between 2022 and 2034 under scenario 1 could avert 2.5 billion cases of pharyngitis, 354 million cases of impetigo, 1.4 million cases of invasive disease, 24 million cases of cellulitis, and 6 million cases of RHD during the vaccinated individuals' lifetime (see Table 3 for scenario 1). This averages to 82 million cases of pharyngitis, 11.8 million cases of impetigo, 45,000 cases of invasive disease, 805,000 cases of cellulitis, and 210,000 cases of RHD averted per birth cohort.

Regionally, we estimated vaccination impact in terms of total cases averted to be highest in Sub-Saharan Africa (see Table 3) for pharyngitis, impetigo, invasive disease, cellulitis, and RHD. By income level, vaccination impact on Strep A cases averted was estimated to be highest in lower-middleincome countries (see Figure 2).

Vaccination impact in terms of cases averted per 1,000 vaccinated individuals was highest in North America for cellulitis and in Sub-Saharan Africa for RHD (see Figure 3). The vaccine impact metric of disease burden averted per 1,000 vaccinated individuals remains the same for any vaccination coverage in each scenario, with the caveat that the Strep A vaccine impact model includes only the direct effects of vaccination and excludes indirect herd effects. As only the direct effect of vaccination was included, the estimated health benefits of Strep A vaccination are likely to be conservative.

#### Vaccine impact on Strep A-related deaths

Globally, we estimated that vaccination at birth for 30 cohorts under scenario 1 could avert 1.9 million deaths resulting from RHD and 79,000 deaths from invasive disease (see Table 4). Over 1 million of these global RHD deaths averted are in Sub-Saharan Africa (see Table 4).

#### Vaccine impact on DALYs

Nationally (see Figure 4), we estimated the combined disability-adjusted life years (DALYs) per 1,000 vaccinated individuals averted due to a Strep A vaccine. This averted burden was highest in Tonga and Sub-Saharan African countries.

#### Vaccine coverage levels and year of introduction

The numbers of fully vaccinated individuals were higher for scenarios 1-2 due to higher levels of vaccine coverage assumed for many of the countries (see Appendix) and hence a higher number of cases were averted in these scenarios compared with scenarios 3-6 (see Table 3). However, a delay in vaccine introduction occurs in scenarios 1–2 and 5–6 which leads to a corresponding delay in vaccination impact compared with scenarios 3–4 where Strep A vaccination was assumed to be introduced in all countries in 2022.

#### Age of vaccination

Cases averted per 1,000 fully vaccinated individuals were higher for pharyngitis and RHD when vaccination was administered to children aged 5 years compared with vaccination at birth (see Figures 2-3). This is because the pre-vaccination burden (cumulative incidence) of pharyngitis and RHD is higher in the 10–20 years after 5 years of age than the cumulative incidence in the 10–20 years after 5 years of 2022–2051.

Similarly, the combined DALYs averted resulting from a Strep A vaccine at the national level (see Figure 4) in countries in Sub-Saharan Africa, South America, and the Caribbean were higher when vaccination was administered at 5 years of age in comparison to vaccination at birth, primarily due to the higher number of RHD cases averted per 1,000 vaccinated individuals after 5 years of age.

# Discussion

We estimated the potential health impact of prospective Strep A vaccination at the global, regional, and national levels and by country-income category, using the Strep A vaccine impact model. Based on the WHO preferred product characteristics for Strep A vaccines,<sup>9</sup> we developed this static cohort model to estimate the lifetime health benefits among the vaccinated cohorts, with a focus on Strep A disease burden averted for pharyngitis, impetigo, invasive disease, cellulitis, and RHD. We analysed strategic scenarios for vaccination at birth and 5 years of age and projected that around one-third of the annual global burden of RHD can be potentially averted by prospective Strep A vaccination. Regionally, vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for RHD. By income level, total vaccine-avertable burdens for pharyngitis, impetigo, invasive disease, cellulitis, and RHD were highest in lower-middle-income countries, primarily due to the demographic effect of larger population sizes among the target ages for vaccination.

Our health impact estimates provide useful decision-making support for clinical development, interpretation of existing data, assessing needs for data collection to close critical evidence gaps, and policy decisions for prioritisation and implementation throughout the end-to-end continuum of discovery, development, and delivery of safe, effective, and affordable (prospective) Strep A vaccines. While the vaccine-avertable disease burden is an important public health priority, the high morbidity and mortality impact on the young adult population also translates into considerable productivity losses from an economic perspective<sup>7,10</sup>. This requires a broader global public health value proposition analysis to infer the end-to-end perspectives of vaccine development to uptake continuum<sup>11–14</sup>, and the global benefits of prospective Strep A vaccines are estimated to be highly positive<sup>15</sup>.

Our study has limitations. We estimated only the direct effect of Strep A vaccination and excluded the indirect effect on preventing pathogen transmission. Evidence on Strep A transmission dynamics would be valuable to develop a transmission dynamic model for estimating the total (direct and indirect) effects of vaccination. Such estimates would plausibly increase the impact of a Strep A vaccine, especially a vaccine administered in the first few years of life, given the peak incidences of severe invasive disease occurring in infants and older adults. Instead of endogenous modeling of transmission dynamics, the impact of indirect herd effects could be extrapolated by specifying a basic multiplier of the direct effect in the static cohort model, similar to the evaluation of *Haemophilus influenzae* type b, pneumococcal, and rotavirus vaccination.<sup>16</sup>

Evidence on the natural history of disease dynamics would be beneficial to simulate disease progression, such as the progression from acute rheumatic fever to RHD. We estimated vaccination impact on Strep A burden averted for pharyngitis, impetigo, invasive disease, cellulitis, and RHD but excluded the immune-mediated sequelae of acute rheumatic fever and acute post-streptococcal glomerulonephritis and the etiological pathway between Strep A infection and those diseases. While

the exclusion of ARF and APSGN underestimates the impact of a vaccine that prevents those diseases, excluding the etiological pathway between infection and immune-mediated sequelae, including RHD, may overestimate the impact of vaccination at 5 years of age and underestimate the impact of infant vaccination. In our model, we assumed that vaccination in 5-year-old children would prevent incident cases of RHD occurring at age of 5 years. However, some proportion of those cases may be averted by an infant vaccination schedule that prevents the infections preceding ARF and RHD. Further epidemiology or immunology studies are required to model this scenario.

The vaccine impact model can be extended to include other Strep A disease states and sequelae to estimate the additional health benefits of vaccination in averting morbidity and mortality attributable to these conditions. The health benefits of vaccination in reducing Strep A infections could lower corresponding antibiotic use (to treat Strep A infections), and the model could capture this feature with the availability of quality data. The vaccine impact projections are based on a hypothetical vaccine that meets the WHO preferred product characteristics,<sup>9</sup> and Strep A vaccines that attain licensure may have varied characteristics. The vaccine coverage assumptions are based on past coverage trends for *Haemophilus influenzae* type B vaccine (Hib3) or the third dose of diphtheria, tetanus, and pertussis vaccine, where Hib3 coverage values were unavailable, and coverage and scale-up of future Strep A vaccines may differ. Also, assumptions for the duration of protection and waning dynamics of vaccine-derived immunity may differ from future evidence generated from clinical trials and effectiveness studies.

In conclusion, based on the WHO preferred product characteristics for Strep A vaccines, we developed a Strep A vaccine impact model to estimate the health benefits of vaccination in terms of disease burden averted for pharyngitis, impetigo, invasive disease, cellulitis, and RHD at the global, regional, national, and country-income levels. The health impact estimates of Strep A vaccination are useful inputs for generating economic impact estimates based on cost-effectiveness analysis<sup>17</sup> and for societal impact estimates based on benefit-cost analysis, thereby collating useful pieces of evidence towards the full value of vaccine assessment<sup>11,18</sup> for Strep A vaccines.

# Methods

#### Strep A vaccine impact model

We developed a static cohort model to estimate the lifetime health benefits of vaccination for 30 cohorts from the year of vaccine introduction (2022-2034) on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and RHD) in terms of episodes/cases, deaths, and disability-adjusted life years (DALYs) averted by vaccination (see Figure 1). The reduction in disease burden is in direct proportion to vaccine efficacy, vaccine coverage, and vaccine-derived immunity.

The pre-vaccination disease burden is based on country- and age-specific incidence rates for cellulitis and RHD and global age-specific prevalence for impetigo from the 2019 Global Burden of Disease (GBD) study<sup>19</sup>. For pharyngitis and invasive disease, the pre-vaccination disease burden is based on global age-specific rates from systematic reviews conducted as part of the Strep A Vaccine Global Consortium (SAVAC) project. Mortality risk was limited to 28 days from hospitalisation for invasive disease and to 10 years from disease onset for RHD. Country- and age-specific rates of Strep A burden were assumed to remain constant in the future. We did not include APSGN and ARF in our analysis due to data limitations on prevalent burden estimates.

Demographic estimates for the country, year and age-specific population, all-cause mortality rates, and remaining life expectancy are based on the 2019 United Nations World Population Prospects<sup>20</sup>. The model uses non-sex specific projected (2020 - 2100) interpolated age-specific (0 - 99 years) population and age-grouped (covering the same age range) all-cause mortality probabilities and remaining life expectancy estimates. Age groups for all-cause mortality and life expectancy are in 5-year bands, apart from 0 - 4 years (age 0 is in a separate group), assuming uniformity within groups for mortality and remaining life expectancy. Any projection of lifetime burden that went beyond 2100 assumed the same population, all-cause mortality, and remaining life expectancy values as for 2100. The country- and age-specific population numbers were used to estimate the population at age of vaccination, and then all-cause mortality probabilities were used to estimate the modelled population at each age over a cohort's lifetime.

Disability weights used for the calculation of years lived with disability are from the GBD study,<sup>21</sup> and YLD (years lived with disability) was attributed to the years of prevalence. The duration for pharyngitis, impetigo, invasive disease, and cellulitis was estimated to be 5 days, 15.5 days, 10 days, and 16.4 days respectively, based on the GBD reported prevalence divided by incidence.<sup>19</sup> The duration for RHD was assumed to be the remaining life expectancy from the onset of the condition.

The vaccine efficacy assumptions are based on the WHO preferred product characteristics for Strep A vaccine, as shown in Table 1.<sup>9</sup> The waning dynamics of vaccine-derived immunity were modelled in two ways: (i) vaccine-induced immune protection at maximum efficacy for 10 years and null thereafter and (ii) waning linearly with an annual reduction in efficacy equivalent to 5% of maximum efficacy for 20 years and null thereafter (i.e., waning to 50% of maximum efficacy after 10 years).

The year of vaccine introduction was assumed to be 2022 or country-specific ranging from 2022 to 2034, with initial coverage at 10% of maximum coverage. The vaccine coverage was assumed to scale up linearly during the first 10 years after introduction to reach either a maximum of 50% coverage for all countries or a country-specific coverage ranging from 9% to 99%. Country-specific coverage values and year of introduction (see Appendix) are based on past trends for Hib3 or the third dose of diphtheria, tetanus, and pertussis vaccine where Hib3 values were unavailable.

Using the model, we analysed six potential scenarios for varied years of vaccine introduction, coverage, and waning dynamics (see Table 2), with vaccination at birth or 5 years of age. We modelled these scenarios for 183 countries (see Table A5) and aggregated results at the global, regional, and country-income levels.

While these vaccination scenarios are hypothetical, the pragmatic vaccination scenarios will become clear during the vaccine introduction discussions at the national (including national immunization technical advisory groups), regional (including regional immunization technical advisory groups), and global (including WHO Strategic Advisory Group of Experts on immunization) levels. However, the vaccine impact metric of disease burden averted per fully vaccinated individual remains the same for any vaccination coverage for a given scenario, with the caveat that the Strep A vaccine impact model includes only the direct effects of vaccination and excludes indirect herd effects.

#### R package and Shiny web application

We developed the Strep A vaccine impact model using the R statistical software<sup>22</sup> and included a user-friendly R Shiny web application. The program code and data for the vaccine impact model is available as an R package, *GASImpactModel* (<u>https://github.com/fionagi/GASImpactModel</u>) and modeling analysis can be conducted through the R Shiny web application (<u>https://github.com/fionagi/GASImpactModel App</u>). Through the web application, the impact of a selected vaccination scenario can be visualized for any of 205 countries. The app shows the predicted lifetime health benefits from age of vaccination associated with the vaccination of multiple cohorts during the period selected. The vaccine impact model can estimate the health benefits of vaccination by calendar year, birth year, and year of vaccination.<sup>23</sup>

#### Role of the funding source

This work was supported, in whole or in part, by the Wellcome Trust [215490/Z/19/Z]. The funders were not involved in the study design, data analysis, data interpretation, and writing of the manuscript. The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the decisions, policy, or views of their affiliated organizations.

#### **Declaration of interests**

We declare no conflict of interest.

#### Contribution

FG, JWC, and KA conceptualized and designed the study. FG and JWC compiled the data sets and conducted the analysis. FG developed the Strep A vaccine impact model and software. DC, DEB, HCM, and JC advised on modeling framework and public health implications. FG and KA wrote the first draft. All authors contributed with critical input, reviewing and editing of the manuscript, and have approved the final version.

#### Acknowledgements

We thank Kate Miller (Telethon Kids Institute) for helpful discussions.

#### ORCID

FG (0000-0001-6302-506X), JWC (0000-0002-1321-9605), DC (0000-0003-1853-0651), DEB (0000-0003-3731-3345), HCM (0000-0001-6434-8290), JC (0000-0002-1182-9792), KA (0000-0003-0563-1576)

#### References

- 1. Carapetis, J. R., Steer, A. C., Mulholland, E. K. & Weber, M. The global burden of group A streptococcal diseases. *Lancet Infect. Dis.* **5**, 685–694 (2005).
- 2. Watkins, D. A. *et al.* Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. *N. Engl. J. Med.* **377**, 713–722 (2017).
- 3. Ralph, A. P. & Carapetis, J. R. Group A Streptococcal Diseases and Their Global Burden. *Microbiol Immunol* **368**, 1–27 (2012).
- 4. Sims Sanyahumbi, A., Colquhoun, S., Wyber, R. & Carapetis, J. R. Global disease burden of group A streptococcus. in *Streptococcus pyogenes : Basic Biology to Clinical Manifestations* (eds. Ferretti, J. J., Stevens, D. L. & Fischetti, V. A.) (University of Oklahoma Health Sciences Center, 2016).
- 5. Wang, D. *et al.* Stroke and rheumatic heart disease: a systematic review of observational studies. *Clin. Neurol. Neurosurg.* **115**, 1575–1582 (2013).
- 6. Karthikeyan, G. & Mayosi, B. M. Is primary prevention of rheumatic fever the missing link in the control of rheumatic heart disease in Africa? *Circulation* **120**, 709–713 (2009).
- Cannon, J., Bessarab, D. C., Wyber, R. & Katzenellenbogen, J. M. Public health and economic perspectives on acute rheumatic fever and rheumatic heart disease. *Med. J. Aust.* 211, 250-252.e1 (2019).
- 8. Fleming-Dutra, K. E. *et al.* Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. *JAMA* **315**, 1864–1873 (2016).
- 9. World Health Organization. WHO preferred product characteristics for group A streptococcus vaccines. https://apps.who.int/iris/handle/10665/279142 (2018).
- 10. Cannon, J. W. *et al.* An economic case for a vaccine to prevent group A streptococcus skin infections. *Vaccine* **36**, 6968–6978 (2018).
- 11. Hutubessy, R. C. W. *et al.* The full value of vaccine assessments (FVVA): A framework to assess and communicate the value of vaccines for investment and introduction decision making. *SSRN Journal* (2021) doi:10.2139/ssrn.3841999.
- 12. Steer, A. C. *et al.* Status of research and development of vaccines for Streptococcus pyogenes. *Vaccine* **34**, 2953–2958 (2016).
- 13. Steer, A. C., Dale, J. B. & Carapetis, J. R. Progress toward a global group a streptococcal vaccine. *Pediatr. Infect. Dis. J.* **32**, 180–182 (2013).
- 14. Vekemans, J. *et al.* The path to group A streptococcus vaccines: world health organization research and development technology roadmap and preferred product characteristics. *Clin. Infect. Dis.* **69**, 877–883 (2019).
- 15. Cadarette, D., Ferranna, M., Cannon, J. & Bloom, D. The full health, economic, and social benefits of Strep A vaccines. *npj Vaccines* (2022).
- Clark, A. *et al.* TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. *Vaccine* **31 Suppl 3**, C19-29 (2013).
- 17. Lee, J.-S. et al. The potential global cost-effectiveness of prospective Strep A vaccines against

various infections caused by Streptococcus pyogenes: a model-based analysis. (2022).

- 18. Cadarette, D., Ferranna, M., Cannon, J. & Bloom, D. The full health, economic, and social benefits of Strep A vaccines. (2022).
- GBD Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 396, 1204–1222 (2020).
- 20. UNDP. World Population Prospects Population Division United Nations. https://population.un.org/wpp/ (2019).
- 21. Salomon, J. A. *et al.* Disability weights for the Global Burden of Disease 2013 study. *Lancet Glob. Health* **3**, e712-23 (2015).
- 22. R Core Team. *R: A language and environment for statistical computing*. (R Foundation for Statistical Computing, 2019).
- 23. Echeverria-Londono, S. *et al.* How can the public health impact of vaccination be estimated? *BMC Public Health* **21**, 2049 (2021).

# Tables

**Table 1. Vaccine efficacy.** The vaccine efficacy assumptions are based on the WHO preferredproduct characteristics for the Strep A vaccine.

Strep A disease state/sequelae	Vaccine efficacy (%)
Pharyngitis	80
Impetigo	80
Invasive disease	70
Cellulitis	70
Rheumatic heart disease	50

Table 2. Vaccination scenarios. Potential vaccination scenarios for varying years of vaccine introduction, coverage, vaccine-derived immunity dynamics, and age of vaccination (at birth or 5 years of age).

Scenario	Year of vaccine introduction	Maximum coverage	Durability of vaccine-derived immunity
1	Country-specific (2022 - 2034)	Country-specific (9 - 99%)	Full efficacy for 10 years
2	Country-specific (2022 - 2034)	Country-specific (9 - 99%)	Linear waning over 20 years
3	2022	50%	Full efficacy for 10 years
4	2022	50%	Linear waning over 20 years
5	Country-specific (2022 - 2034)	50%	Full efficacy for 10 years
6	Country-specific (2022 - 2034)	50%	Linear waning over 20 years

Table 3. Vaccine impact at the regional and global levels. The vaccine impact on cases averted is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination at birth for 30 birth cohorts from year of vaccine introduction on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease).

	Sconarios	Fully vaccinated	Cases averted through vaccination (thousands) (range for scenarios 1-2 and 3-6)				
ONTEGIONS	Scenarios	individuals (millions)	Pharyngitis	Impetigo	Invasive disease	Cellulitis	Rheumatic heart disease
South Asia	1-2*	657	(578,344, 606,913)	(76,156, 80,716)	(291, 310)	(3,880, 3,992)	(1,041, 1,466)
South Asia	3-6	(381, 388)	(334,999, 357,905)	(44,117, 47,620)	(169, 183)	(2,246, 2,352)	(608, 870)
Europe &	1-2*	226	(199,636, 209,585)	(26,231, 27,796)	(100, 106)	(2,027, 2,104)	(102, 120)
Central Asia	3-6	(122, 124)	(107,661, 114,573)	(14,146, 15,197)	(54, 58)	(1,115, 1,171)	(53, 62)
Middle East	1-2*	218	(192,160, 201,701)	(25,266, 26,776)	(96, 102)	(1,253, 1,258)	(348, 407)
Africa	3-6	(121, 122)	(106,638, 112,917)	(14,025, 14,991)	(53, 57)	(693, 701)	(196, 232)
Sub-Saharan	1-2*	918	(799,501, 838,027)	(105,671, 112,075)	(407, 433)	(5,548, 5,635)	(3,635, 4,633)
Africa	3-6	(583, 607)	(505,846, 553,384)	(62,933, 74,061)	(258, 286)	(3,562, 3,777)	(2,285, 3,030)
Latin America	1-2*	184	(162,482, 170,555)	(21,361, 22,637)	(81, 87)	(3,544, 3,949)	(413, 501)
& Caribbean	3-6	(109, 113)	(95,898, 104,796)	(12,608, 13,913)	(48, 53)	(2,091, 2,435)	(244, 306)
East Asia &	1-2*	575	(507,378, 532,590)	(66,695, 70,679)	(254, 270)	(3,261, 3,354)	(763, 860)
Pacific	3-6	(317, 329)	(279,857, 304,513)	(36,790, 40,426)	(140, 155)	(1,837, 1,954)	(414, 483)
North	1-2*	107	(94,334, 99,039)	(12,395, 13,134)	(47, 50)	(4,145, 4,506)	(4, 4)
America	3-6	(58 <i>,</i> 58)	(51,094, 53,879)	(6,714, 7,145)	(26, 27)	(2,245, 2,451)	(2, 2)
Global	1-2*	2,886	(2,533,834, 2,658,410)	(333,775, 353,814)	(1,277, 1,359)	(23,657, 24,797)	(6,306, 7,991)
Giubai	3-6	(1,690, 1,741)	(1,481,995, 1,601,967)	(195,332, 213,353)	(748, 820)	(13,789, 14,843)	(3,802, 4,985)

\* Same number of fully vaccinated individuals for scenarios 1 and 2.

Table 4. Vaccine impact (deaths averted by vaccination at birth) at the regional and global levels. The vaccine impact on deaths averted (in thousands) is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination administered at birth for 30 birth cohorts from year of vaccine introduction on Strep A disease burden (invasive disease and rheumatic heart disease).

UN regions	Scenarios	Fully vaccinated individuals (millions)	Deaths averted by vaccination at birth (thousands) (range for scenarios 1-2 and 3-6)	
			Invasive disease	Rheumatic heart disease
South Asia	1-2*	657	(18, 19)	(313, 440)
	3-6	(381, 388)	(10, 11)	(183, 261)
Europe & Central Asia	1-2*	226	(6, 7)	(30, 36)
	3-6	(122, 124)	(3, 4)	(16, 18)
Middle East & North Africa	1-2*	218	(6, 6)	(103, 121)
	3-6	(121, 122)	(3, 4)	(58, 69)
Sub-Saharan Africa	1-2*	918	(25, 27)	(1,092, 1,392)
	3-6	(583, 607)	(16, 18)	(686, 910)
Latin America & Caribbean	1-2*	184	(5, 5)	(122, 148)
	3-6	(109, 113)	(3, 3)	(72, 91)
East Asia & Pacific	1-2*	575	(16, 17)	(229, 258)
	3-6	(317, 329)	(9, 9)	(124, 145)
North America	1-2*	107	(3, 3)	(0.11, 0.11)
	3-6	(58, 58)	(2, 2)	(0.06, 0.06)
Global	1-2*	2,886	(79, 83)	(1,889, 2,395)
	3-6	(1,690, 1,741)	(46, 50)	(1,139, 1,494)

\* Same number of fully vaccinated individuals for scenarios 1 and 2.

# **Figures**

**Figure 1. Strep A vaccine impact model.** The static cohort model estimates the projected health impact of Strep A vaccination among the vaccinated cohorts over their lifetime in terms of burden averted for pharyngitis, invasive disease, impetigo, cellulitis, and rheumatic heart disease.



DALYs - Disability adjusted life years

UNWPP – United Nations World Population Prospects

WHO PPC – World Health Organization Preferred Product Characteristics for Group A Streptococcus Vaccines

**Figure 2. Vaccine impact at the country-income levels.** The vaccine impact on cases averted (in thousands) is stratified by income levels of countries (World Bank income classification), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts from year of vaccine introduction on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease). The vertical bars show the estimates for scenario 1, and the error bars show the range across scenarios 1-6. Note the differences in scale between the left panel (pharyngitis and impetigo) and the right panel (invasive, cellulitis and rheumatic heart disease).

#### Vaccination at birth



Figure 3. Vaccine impact at the regional and global levels. The vaccine impact on cases averted per 1,000 fully vaccinated individuals is stratified at the regional (United Nations regions) and global levels for different scenarios (estimate for scenario 1 and range across the six scenarios), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts from year of vaccine introduction on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease). The vertical bars show the estimates for scenarios 1, 3, and 5 (which are equal), and the error bars show the estimates for scenarios 2, 4, and 6 (which are equal).

#### Vaccination at birth



Condition

**Figure 4. Vaccine impact at the national level.** The vaccine impact on disability-adjusted life years (DALYs) averted per 1,000 fully vaccinated individuals is shown for 183 countries, based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts from year of vaccine introduction on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease) for scenario 1.

#### Vaccination at birth

Disability-adjusted life years (DALYs) averted per 1000 fully vaccinated individuals



#### Vaccination at 5 years of age

Disability-adjusted life years (DALYs) averted per 1000 fully vaccinated individuals



# Appendix

#### Table A1. Vaccine impact (cases averted by vaccination at 5 years of age) at the regional and global

**levels.** The vaccine impact on cases averted is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination administered at 5 years of age for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease).

	Comprise	Fully vaccinated	Y ated Cases averted by vaccination at 5 years of age (thousands) (range for scenarios 1-2 and 3-6)				ısands)
UN regions	scenarios	individuals (millions)	Pharyngitis	Impetigo	Invasive disease	Cellulitis	Rheumatic heart disease
Courth Asia	1-2*	688	(941,532, 1,214,642)	(63,183, 72,453)	(72, 80)	(3,921, 4,118)	(2,077, 2,480)
South Asia	3-6	(398, 405)	(544,948, 715,582)	(36,569, 42,684)	(42, 47)	(2,268, 2,424)	(1,211, 1,469)
Europe &	1-2*	230	(314,454, 405,725)	(21,104, 24,199)	(24, 27)	(1,772, 1,934)	(160, 165)
Central Asia	3-6	(124, 126)	(169,651, 222,327)	(11,386, 13,260)	(13, 15)	(981, 1,085)	(83, 86)
Middle East &	1-2*	217	(297,569, 383,917)	(19,970, 22,899)	(23, 25)	(1,160, 1,200)	(526, 556)
North Africa	3-6	(121, 122)	(165,632, 215,138)	(11,115, 12,832)	(13, 14)	(644, 670)	(297, 317)
Sub-Saharan	1-2*	884	(1,206,793, 1,556,228)	(80,963, 92,852)	(92, 102)	(5,070, 5,256)	(6,419, 6,501)
Africa	3-6	(558, 585)	(761,012, 1,028,952)	(51,052, 61,395)	(58, 68)	(3,242, 3,527)	(4,004, 4,248)
Latin America	1-2*	191	(262,127, 338,193)	(17,591, 20,172)	(20, 22)	(3,023, 3,276)	(710, 728)
& Caribbean	3-6	(113, 118)	(154,736, 208,235)	(10,384, 12,420)	(12, 14)	(1,782, 2,022)	(419, 446)
East Asia &	1-2*	592	(811,126, 1,046,509)	(54,436, 62,420)	(62, 69)	(2,549, 2,602)	(1,154, 1,162)
Pacific	3-6	(327, 340)	(447,406, 599,972)	(30,026, 35,786)	(34, 39)	(1,435, 1,518)	(626, 654)
North	1-2*	108	(148,060, 191,037)	(9,937, 11,394)	(11, 13)	(4,639, 5,105)	(2, 3)
America	3-6	(58, 59)	(80,100, 103,928)	(5,376, 6,199)	(6, 7)	(2,509, 2,777)	(1, 1)
Global	1-2*	2,911	(3,981,660, 5,136,251)	(267,184 <i>,</i> 306,388)	(305, 338)	(22,134, 23,493)	(11,049, 11,594)
	3-6	(1,699,	(2,323,484,	(155,909,	(178, 204)	(12,861,	(6,641, 7,222)

1,754)	3,094,135)	184,577)	14,022)	

\* Same number of fully vaccinated individuals for scenarios 1 and 2.

#### Table A2. Vaccine impact (DALYs averted by vaccination at birth) at the regional and global levels.

The vaccine impact on DALYs averted (in thousands) is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination administered at birth for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease).

UN regions	Scenarios	Fully vaccinated individuals (millions)	DALYs a	<b>DALYs averted by vaccination at birth</b> (thousands) (range for scenarios 1-2 and 3-6)			
			Pharyngitis	Impetigo	Invasive disease	Cellulitis	Rheumatic heart disease
South Asia	1-2*	657	(206, 216)	(19, 21)	(1,321, 1,400)	(9, 9)	(24,398, 32,854)
	3-6	(381, 388)	(119, 127)	(11, 12)	(764, 820)	(5, 5)	(14,229, 19,354)
Europe & Central Asia	1-2*	226	(71, 75)	(7, 7)	(495, 525)	(5, 5)	(2,387, 2,720)
	3-6	(122, 124)	(38, 41)	(4, 4)	(267, 284)	(3, 3)	(1,233, 1,413)
Middle East & North Africa	1-2*	218	(68, 72)	(6, 7)	(458, 485)	(3, 3)	(8,394, 9,507)
	3-6	(121, 122)	(38, 40)	(4, 4)	(251, 271)	(2, 2)	(4,678, 5,410)
Sub-Saharan Africa	1-2*	918	(285, 298)	(27, 29)	(1,710, 1,813)	(13, 13)	(79,908, 98,237)
	3-6	(583, 607)	(180, 197)	(17, 19)	(1,068, 1,191)	(8, 9)	(49,637, 63,933)
Latin America & Caribbean	1-2*	184	(58, 61)	(5, 6)	(398, 422)	(8, 9)	(10,341, 12,141)
	3-6	(109, 113)	(34, 37)	(3, 4)	(235, 256)	(5, 6)	(6,095, 7,338)
East Asia & Pacific	1-2*	575	(181, 190)	(17, 18)	(1,240, 1,314)	(7, 8)	(19,143, 21,000)
	3-6	(317, 329)	(100, 108)	(9, 10)	(682, 739)	(4, 4)	(10,356, 11,603)
North America	1-2*	107	(34, 35)	(3, 3)	(239 <i>,</i> 253)	(9, 10)	(22, 22)

	3-6	(58, 58)	(18, 19)	(2, 2)	(128,	(5, 6)	(12, 12)
					138)		
Global	1-2*	2,886	(902, 946)	(85, 90)	(5,862,	(54, 57)	(144,593,
					6,212)		176,481)
	3-6	(1,690, 1,741)	(527, 570)	(50, 54)	(3,396,	(32, 34)	(86,241,
					3,699)		109,064)

\* Same number of fully vaccinated individuals for scenarios 1 and 2.

#### Table A3. Vaccine impact (DALYs averted by vaccination at 5 years of age) at the regional and

global levels. The vaccine impact on DALYs averted (in thousands) is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination administered at 5 years of age for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease).

UN regions	Scenarios	Fully vaccinated	DALYs averted by vaccination at 5 years of age (thousands (range for scenarios 1-2 and 3-6)				(thousands)
		(millions)	Pharyngitis	Impetigo	Invasive disease	Cellulitis	Rheumatic heart disease
South Asia	1-2*	688	(335, 432)	(16, 18)	(366, 403)	(9, 9)	(45,824, 52,767)
	3-6	(398, 405)	(194, 255)	(9, 11)	(212, 236)	(5, 6)	(26,687, 31,032)
Europe & Central Asia	1-2*	230	(112, 144)	(5, 6)	(134, 148)	(4, 4)	(3,563, 3,570)
	3-6	(124, 126)	(60, 79)	(3, 3)	(72, 80)	(2, 2)	(1,842, 1,853)
Middle East & North Africa	1-2*	217	(106, 137)	(5, 6)	(121, 134)	(3, 3)	(12,008, 12,368)
	3-6	(121, 122)	(59, 77)	(3, 3)	(67, 75)	(1, 2)	(6,702, 7,049)
Sub-Saharan Africa	1-2*	884	(430, 554)	(21, 24)	(438, 481)	(12, 12)	(131,948, 133,244)
	3-6	(558, 585)	(271, 366)	(13, 16)	(273, 317)	(7, 8)	(81,343, 86,674)
Latin America & Caribbean	1-2*	191	(93, 120)	(4, 5)	(110, 122)	(7, 8)	(16,831, 16,905)
	3-6	(113, 118)	(55, 74)	(3, 3)	(65, 74)	(4, 5)	(9,929, 10,252)
East Asia & Pacific	1-2*	592	(289, 372)	(14, 16)	(339, 375)	(6, 6)	(27,130, 27,490)
	3-6	(327, 340)	(159, 214)	(8, 9)	(186, 211)	(3, 3)	(14,657, 15,220)

North America	1-2*	108	(53, 68)	(3, 3)	(64, 71)	(11, 12)	(13, 15)
	3-6	(58, 59)	(29, 37)	(1, 2)	(34, 39)	(6, 6)	(7, 8)
Global	1-2*	2,911	(1,417, 1,828)	(68, 78)	(1,573,	(51, 54)	(237,317,
					1,733)		246,359)
	3-6	(1,699, 1,754)	(827, 1,101)	(40, 47)	(909,	(29, 32)	(141,167,
					1,030)		152,088)

 $\ensuremath{^*}$  Same number of fully vaccinated individuals for scenarios 1 and 2.

Table A4. Vaccine impact (deaths averted by vaccination at 5 years of age) at the regional and global levels. The vaccine impact on deaths averted (in thousands) is presented at the regional (United Nations regions) and global levels for different scenarios, based on the lifetime health impact of vaccination administered at 5 years of age for 30 vaccinated cohorts on Strep A disease burden (invasive disease and rheumatic heart disease).

UN regions	Scenarios	Fully vaccinated individuals (millions)	Deaths averted by vaccination at 5 years of age (thousands) (range for scenarios 1-2 and 3-6)	
			Invasive disease	Rheumatic heart
				disease
South Asia	1-2*	688	(5, 6)	(624, 745)
	3-6	(398, 405)	(3, 4)	(364, 441)
Europe & Central Asia	1-2*	230	(2, 2)	(48, 49)
	3-6	(124, 126)	(1, 1)	(25, 25)
Middle East & North Africa	1-2*	217	(2, 2)	(156, 165)
	3-6	(121, 122)	(1, 1)	(88, 94)
Sub-Saharan Africa	1-2*	884	(7, 8)	(1,928, 1,953)
	3-6	(558, 585)	(4, 5)	(1,203, 1,276)
Latin America & Caribbean	1-2*	191	(1, 2)	(210, 216)
	3-6	(113, 118)	(1, 1)	(124, 132)
East Asia & Pacific	1-2*	592	(5, 5)	(346, 349)
	3-6	(327, 340)	(3, 3)	(188, 196)
North America	1-2*	108	(1, 1)	(0.07, 0.08)
	3-6	(58, 59)	(0.45, 0.52)	(0.04, 0.04)
Global	1-2*	2,911	(23, 26)	(3,313, 3,476)
	3-6	(1,699, 1,754)	(13, 15)	(1,992, 2,166)

\* Same number of fully vaccinated individuals for scenarios 1 and 2.

#### Table A5. Country-specific coverage and year of introduction for Strep A vaccination.

Country	Vaccine coverage (%)	Vaccine introduction (year)
Afghanistan	66	2030
Albania	99	2025
Algeria	91	2026
Angola	59	2027
Antigua and Barbuda	95	2027
Argentina	86	2027
Armenia	92	2022
Australia	94	2025
Austria	85	2030
Azerbaijan	95	2026
Bahamas, The	90	2027
Bahrain	99	2027
Bangladesh	98	2025
Barbados	95	2026
Belarus	9	2030
Belgium	97	2027
Belize	96	2028
Benin	76	2026
Bhutan	97	2028
Bolivia	83	2027
Bosnia and Herzegovina	62	2032
Botswana	95	2022
Brazil	83	2027
Brunei Darussalam	99	2030
Bulgaria	92	2027
Burkina Faso	91	2022
Burundi	90	2022
Cabo Verde	99	2025
Cambodia	92	2026
Cameroon	79	2027
Canada	91	2025
Central African Republic	47	2028
Chad	41	2030
Chile	95	2029
China	99	2028
Colombia	92	2027

Comoros	91	2025
Congo, Dem. Rep.	81	2028
Congo, Rep.	75	2025
Costa Rica	94	2025
Côte d'Ivoire	82	2025
Croatia	94	2030
Cuba	99	2028
Cyprus	97	2029
Czech Republic / Czechia	94	2030
Denmark	97	2029
Djibouti	84	2025
Dominican Republic	90	2027
Ecuador	85	2027
Egypt, Arab Rep.	95	2028
El Salvador	81	2027
Equatorial Guinea	25	2030
Eritrea	95	2022
Estonia	92	2027
Eswatini	90	2022
Ethiopia	72	2027
Fiji	99	2022
Finland	91	2027
France	95	2029
Gabon	70	2028
Gambia, The	93	2025
Georgia	93	2025
Germany	92	2027
Ghana	97	2022
Greece	99	2027
Grenada	96	2028
Guatemala	86	2027
Guinea	45	2030
Guinea-Bissau	88	2025
Guyana	95	2025
Haiti	64	2028
Honduras	90	2027
Hungary	99	2029
Iceland	91	2029
India	89	2025

Indonesia	79	2032
Iran, Islamic Rep.	99	2027
Iraq	84	2027
Ireland	94	2027
Israel	98	2027
Italy	94	2027
Jamaica	98	2027
Japan	99	2029
Jordan	96	2031
Kazakhstan	98	2029
Кепуа	92	2022
Kiribati	95	2022
Korea, Dem. People's Rep.	97	2028
Korea, Rep.	98	2028
Kuwait	99	2027
Kyrgyz Republic	92	2025
Lao PDR	68	2028
Latvia	96	2027
Lebanon	85	2031
Lesotho	93	2025
Liberia	84	2025
Libya	97	2027
Lithuania	92	2027
Luxembourg	99	2027
Madagascar	75	2025
Malawi	92	2022
Malaysia	99	2028
Maldives	99	2028
Mali	71	2025
Malta	97	2030
Mauritania	81	2025
Mauritius	97	2025
Mexico	88	2030
Micronesia, Fed. Sts.	59	2025
Moldova	92	2027
Mongolia	99	2026
Montenegro	87	2033
Morocco	99	2025
Mozambique	80	2025

Myanmar	91	2026
Namibia	89	2025
Nepal	91	2026
Netherlands	93	2029
New Zealand	92	2025
Nicaragua	98	2025
Niger	89	2025
Nigeria	57	2028
North Macedonia	91	2030
Norway	96	2027
Oman	99	2029
Pakistan	75	2027
Panama	88	2027
Papua New Guinea	61	2027
Paraguay	88	2027
Peru	84	2027
Philippines	65	2032
Poland	95	2029
Portugal	99	2029
Qatar	98	2027
Romania	86	2032
Russian Federation	97	2030
Rwanda	97	2022
Samoa	34	2030
São Tomé and Principe	95	2022
Saudi Arabia	96	2027
Senegal	82	2022
Serbia	96	2029
Seychelles	99	2025
Sierra Leone	90	2022
Singapore	96	2029
Slovak Republic / Slovakia	96	2029
Slovenia	93	2029
Solomon Islands	85	2024
Somalia	42	2030
South Africa	74	2024
South Sudan	49	2030
Spain	94	2029
Sri Lanka	99	2030
-		

St. Lucia	95	2027
St. Vincent and the Grenadines	97	2028
Sudan	93	2025
Suriname	95	2030
Sweden	97	2029
Switzerland	95	2029
Syrian Arab Republic	48	2033
Tajikistan	96	2026
Tanzania	98	2025
Thailand	97	2030
Timor-Leste	83	2030
Тодо	88	2025
Tonga	81	2024
Trinidad and Tobago	99	2026
Tunisia	97	2030
Turkey	98	2029
Turkmenistan	99	2026
Uganda	93	2022
Ukraine	39	2033
United Arab Emirates	99	2025
United Kingdom	94	2026
United States	92	2027
Uruguay	91	2029
Uzbekistan	98	2025
Vanuatu	85	2025
Venezuela, RB	60	2034
Vietnam	75	2033
Yemen, Rep.	65	2027
Zambia	90	2025
Zimbabwe	89	2022

Figure A1. Vaccine impact (DALYs averted) at the country-income level. The vaccine impact on DALYs averted (in thousands) is stratified by income levels of countries (World Bank income classification), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease). The vertical bars show the estimates for scenario 1, and the error bars show the range across scenarios 1-6. Note the differences in scale between the left panel (pharyngitis, impetigo and cellulitis) and the right panel (invasive and rheumatic heart disease).

Vaccination at birth





Condition

Vaccination at 5 years of age

Rheumatic heart disease Condition

**Figure A2. Vaccine impact (deaths averted) at the country-income level.** The vaccine impact on deaths averted (in thousands) is stratified by income levels of countries (World Bank income classification), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden (invasive disease and rheumatic heart disease). The vertical bars show the estimates for scenario 1, and the error bars show the range across scenarios 1-6. Note the differences in scale between the left panel (invasive disease) and the right panel (rheumatic heart disease). For rheumatic heart disease in high-income countries, the range of values for age 0 is (0.3, 0.6) and for age 5 (0.4, 0.7).

#### Vaccination at birth

0

Invasive disease

Condition



0

Rheumatic heart disease Condition

#### Figure A3. Vaccine impact (DALYs averted per 1,000 fully vaccinated individuals) at the regional

and global levels. The vaccine impact on DALYs averted per 1,000 fully vaccinated individuals is stratified at the regional (United Nations regions) and global levels for different scenarios (estimate for scenario 1 and range across the six scenarios), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease). The vertical bars show the estimates for scenarios 1, 3, and 5 (which are equal), and the error bars show the estimates for scenarios 2, 4, and 6 (which are equal).

#### 150 DALYs averted (per 1000 fully vaccinated individuals) DALYs averted (per 1000 fully vaccinated individuals) 2.0 Region South Asia 100 Europe & Central Asia Middle East & North Africa Sub-Saharan Africa Latin America & Caribbean East Asia & Pacific 50 North America Global 0.0 Pharyngitis Impetigo Invasive disease Cellulitis Rheumatic heart disease

#### Vaccination at birth



Condition

#### Region South Asia Europe & Central Asia Middle East & North Africa Sub-Saharan Africa Latin America & Caribbean East Asia & Pacific North America Global

Condition

#### Vaccination at 5 years of age

Figure A4. Vaccine impact (deaths averted per 1,000 fully vaccinated individuals) at the regional and global levels. The vaccine impact on deaths averted per 1,000 fully vaccinated individuals is stratified at the regional (United Nations regions) and global levels for different scenarios (estimate for scenario 1 and range across the six scenarios), based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden that results in death (invasive disease and rheumatic heart disease). The vertical bars show the estimates for scenarios 1, 3, and 5 (which are equal), and the error bars show the estimates for scenarios 2, 4, and 6 (which are equal).

#### Vaccination at birth



#### Region

South Asia Europe & Central Asia Middle East & North Africa Sub-Saharan Africa Latin America & Caribbean East Asia & Pacific North America Global





## Region

South Asia

Europe & Central Asia Middle East & North Africa Sub-Saharan Africa Latin America & Caribbean East Asia & Pacific North America Global

**Figure A5. Vaccine impact (cases averted per 1,000 fully vaccinated individuals) at the national level.** The vaccine impact on cases averted per 1,000 fully vaccinated individuals is shown for 183 countries, based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden (pharyngitis, impetigo, invasive disease, cellulitis, and rheumatic heart disease) for scenario 1.

#### Vaccination at birth

Cases averted per 1000 fully vaccinated individuals



#### Vaccination at 5 years of age

Cases averted per 1000 fully vaccinated individuals



**Figure A6. Vaccine impact (deaths averted per 1,000 fully vaccinated individuals) at the national level.** The vaccine impact on deaths averted per 1,000 fully vaccinated individuals is shown for 183 countries, based on the lifetime health impact of vaccination at birth or 5 years of age for 30 vaccinated cohorts on Strep A disease burden resulting in death (invasive disease and rheumatic heart disease) for scenario 1.

#### Vaccination at birth

Deaths averted per 1000 fully vaccinated individuals



#### Vaccination at 5 years of age

Deaths averted per 1000 fully vaccinated individuals

